J. Mark FitzGerald

10.2k total citations · 3 hit papers
110 papers, 6.2k citations indexed

About

J. Mark FitzGerald is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, J. Mark FitzGerald has authored 110 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Physiology, 72 papers in Pulmonary and Respiratory Medicine and 14 papers in Epidemiology. Recurrent topics in J. Mark FitzGerald's work include Asthma and respiratory diseases (79 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (37 papers) and Respiratory and Cough-Related Research (36 papers). J. Mark FitzGerald is often cited by papers focused on Asthma and respiratory diseases (79 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (37 papers) and Respiratory and Cough-Related Research (36 papers). J. Mark FitzGerald collaborates with scholars based in Canada, United States and United Kingdom. J. Mark FitzGerald's co-authors include Mohsen Sadatsafavi, Ian Pavord, Guy Brusselle, Pascal Chanez, Lynn E. Katz, Oliver N. Keene, Mark C. Liu, Steven W. Yancey, Alfredo Chetta and Héctor Ortega and has published in prestigious journals such as New England Journal of Medicine, The Lancet and PLoS ONE.

In The Last Decade

J. Mark FitzGerald

110 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

2014 1.6k citations Héctor Ortega, Mark C. Liu et al. New England Journal of Medicine profile →
Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma

2018 366 citations Paul M. O’Byrne, J. Mark FitzGerald et al. New England Journal of Medicine profile →
As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma

2018 303 citations Eric D. Bateman, Helen K. Reddel et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Mark FitzGerald Canada	36	4.0k	3.9k	739	628	620	110	6.2k
Tricia M. McKeever United Kingdom	49	2.4k 0.6×	3.5k 0.9×	651 0.9×	452 0.7×	1.3k 2.1×	176	7.1k
José A. Castro‐Rodríguez Chile	41	4.9k 1.2×	4.2k 1.1×	507 0.7×	772 1.2×	1.3k 2.1×	212	7.3k
Sidney S. Braman United States	31	3.9k 1.0×	5.2k 1.3×	563 0.8×	647 1.0×	652 1.1×	93	7.3k
Gene Colice United States	45	4.0k 1.0×	5.2k 1.3×	897 1.2×	958 1.5×	617 1.0×	227	7.9k
J. Mark FitzGerald Canada	26	4.1k 1.0×	3.2k 0.8×	884 1.2×	889 1.4×	277 0.4×	85	5.4k
J. Mark FitzGerald Canada	34	2.0k 0.5×	2.4k 0.6×	423 0.6×	204 0.3×	637 1.0×	108	4.8k
Seif O. Shaheen United Kingdom	33	2.2k 0.6×	2.0k 0.5×	344 0.5×	451 0.7×	481 0.8×	93	4.7k
Anne L. Fuhlbrigge United States	39	3.9k 1.0×	3.0k 0.8×	420 0.6×	541 0.9×	403 0.7×	115	5.3k
Angelo Guido Corsico Italy	36	2.4k 0.6×	2.9k 0.7×	317 0.4×	633 1.0×	183 0.3×	207	4.8k
Jinping Zheng China	25	2.6k 0.7×	5.0k 1.3×	406 0.5×	273 0.4×	539 0.9×	162	6.4k

Countries citing papers authored by J. Mark FitzGerald

Since Specialization

Citations

This map shows the geographic impact of J. Mark FitzGerald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Mark FitzGerald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Mark FitzGerald more than expected).

Fields of papers citing papers by J. Mark FitzGerald

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Mark FitzGerald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Mark FitzGerald. The network helps show where J. Mark FitzGerald may publish in the future.

Co-authorship network of co-authors of J. Mark FitzGerald

This figure shows the co-authorship network connecting the top 25 collaborators of J. Mark FitzGerald. A scholar is included among the top collaborators of J. Mark FitzGerald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Mark FitzGerald. J. Mark FitzGerald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gauvreau, Gail M., Jens M. Hohlfeld, J. Mark FitzGerald, et al.. (2023). Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. European Respiratory Journal. 61(3). 2201193–2201193. 40 indexed citations

Reddel, Helen K., Paul M. O’Byrne, J. Mark FitzGerald, et al.. (2021). Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma. The Journal of Allergy and Clinical Immunology In Practice. 9(8). 3069–3077.e6. 18 indexed citations

FitzGerald, J. Mark, Peter J. Barnes, Bradley E. Chipps, et al.. (2020). The burden of exacerbations in mild asthma: a systematic review. ERJ Open Research. 6(3). 359–2019. 43 indexed citations

Gruffydd‐Jones, Kevin, Mike Thomas, Miguel Román-Rodríguez, et al.. (2019). <p>Asthma impacts on workplace productivity in employed patients who are symptomatic despite background therapy: a multinational survey</p>. Journal of Asthma and Allergy. Volume 12. 183–194. 34 indexed citations

Yaghoubi, Mohsen, Amin Adibi, Abdollah Safari, J. Mark FitzGerald, & Mohsen Sadatsafavi. (2019). The Projected Economic and Health Burden of Uncontrolled Asthma in the United States. American Journal of Respiratory and Critical Care Medicine. 200(9). 1102–1112. 202 indexed citations

Poureslami, Iraj, Jessica Shum, Richard Lester, et al.. (2018). A pilot randomized controlled trial on the impact of text messaging check-ins and a web-based asthma action plan versus a written action plan on asthma exacerbations. Journal of Asthma. 56(8). 897–909. 19 indexed citations

Filho, Fernando Sergio Leitão, Nawaf Alotaibi, Sheena Tam, et al.. (2018). Sputum Microbiome Is Associated with 1-Year Mortality after Chronic Obstructive Pulmonary Disease Hospitalizations. American Journal of Respiratory and Critical Care Medicine. 199(10). 1205–1213. 98 indexed citations

Chen, Wenjia, J. Mark FitzGerald, Don D. Sin, & Mohsen Sadatsafavi. (2017). Excess economic burden of comorbidities in COPD: a 15-year population-based study. European Respiratory Journal. 50(1). 1700393–1700393. 45 indexed citations

FitzGerald, J. Mark, et al.. (2017). The impact of inappropriate use of short acting beta agonists in asthma. Respiratory Medicine. 131. 135–140. 68 indexed citations

10.

Silkoff, Philip E., Michel Laviolette, Dileep Kumar Singh, et al.. (2016). Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study. Respiratory Research. 17(1). 43–43. 29 indexed citations

11.

Chen, Wenjia, Larry D. Lynd, J. Mark FitzGerald, et al.. (2016). Excess medical costs in patients with asthma and the role of comorbidity. European Respiratory Journal. 48(6). 1584–1592. 35 indexed citations

12.

Ortega, Héctor, Mark Liu, Ian Pavord, et al.. (2014). Late-breaking abstract: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal. 44(Suppl 58). 2906–2906. 1 indexed citations

13.

Ortega, Héctor, Mark C. Liu, Ian Pavord, et al.. (2014). Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. New England Journal of Medicine. 371(13). 1198–1207. 1591 indexed citations breakdown →

14.

Gan, Wenqi, J. Mark FitzGerald, Chris Carlsten, Mohsen Sadatsafavi, & Michael Bräuer. (2013). Associations of Ambient Air Pollution with Chronic Obstructive Pulmonary Disease Hospitalization and Mortality. American Journal of Respiratory and Critical Care Medicine. 187(7). 721–727. 222 indexed citations

15.

FitzGerald, J. Mark, et al.. (2009). Montelukast as Add‐On Therapy to Inhaled Corticosteroids in the Management of Asthma (The SAS Trial). Canadian Respiratory Journal. 16(A). 5A–14A. 16 indexed citations

16.

Johnston, James C., Neal Shahidi, Mohsen Sadatsafavi, & J. Mark FitzGerald. (2009). Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. PLoS ONE. 4(9). e6914–e6914. 325 indexed citations

17.

Etminan, Mahyar, et al.. (2008). Inhaled Corticosteroids and the Risk of Fractures in Older Adults. Drug Safety. 31(5). 409–414. 37 indexed citations

18.

FitzGerald, J. Mark. (2004). Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax. 59(7). 550–556. 122 indexed citations

19.

Marra, Carlo A., et al.. (2004). Factors influencing quality of life in patients with active tuberculosis. Health and Quality of Life Outcomes. 2(1). 58–58. 89 indexed citations

20.

Little, A, et al.. (1995). Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. British Journal of Cancer. 72(3). 683–690. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact